Hepatitis B virus
Drug research and approvals for hepatitis B virus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 146 studies of hepatitis B virus are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 146
- Trials authorized in Canada: 26
- FDA orphan approvals: 0
- EU medicines: 6
- A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal…NCT07944482 · Phase 1 · Fujian Akeylink Biotechnology Co., Ltd. · starts Jul 3, 2026
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant…NCT07855172 · Phase 1 / Phase 2 · Serum Institute of India Pvt. Ltd. · starts Nov 1, 2026
- Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)NCT07855029 · Not reported · Zhiliang Gao · starts Jul 1, 2026
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)NCT07852091 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)NCT07845058 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of LiverNCT07816094 · Phase 4 · Bangladesh Medical University · starts Jan 1, 2026
- Study of BK1803 in Healthy InfantsNCT07793513 · Phase 3 · Tanabe Pharma Corporation · starts Oct 21, 2026
- A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis BNCT07771140 · Phase 1 · Sunshine Lake Pharma Co., Ltd. · starts Dec 2, 2025
- Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCNCT07769827 · Not applicable · Jinling Hospital, China · starts Dec 26, 2025
How its trials ended
1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 397 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.
- Completed, result not reported64639%
- Status unknown38923%
- Ongoing24214%
- Met its primary endpoint23514%
- Stopped: other or unclear754%
- Stopped: sponsor or business decision292%
- Missed its primary endpoint221%
- Stopped: enrollment or feasibility221%
- Stopped: lack of efficacy7<1%
- Stopped: safety7<1%
| May 14, 2025 | A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of ALG-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / Tenofovir disoproxil | Aligos Therapeutics | Ongoing |
| Nov 6, 2024 | A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101 | Arbutus Biopharma | Closed |
| Sep 23, 2024 | A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / Daplusiran-tomligisiran (GSK5637608/JNJ-73763989) | GSK | Ongoing |
| Jul 2, 2024 | A multicenter, randomized, double-blind, placebo- controlled study to assess the efficacy and safety of treatment with bepirovirsen in participants living with…Bepirovirsen (GSK3228836) | GSK | Ongoing |
| Dec 16, 2022 | A phase 2 study to evaluate the safety, tolerability, and efficacy of regimens containing VIR-2218, VIR-3434, and/or peg-ifn in subjects with chronic hepatitis…Elebsiran (VIR-2218)/ Tobevibart (VIR-3434)/ Peginterferon ALFA-2A | Vir Biotechnology | Ongoing |
| Nov 9, 2022 | Phase 3 multicenter, randomized, double-blind, study to assess the efficacy and safety of treatment with bepirovirsen in nucleos(t)ide analogue treated…Bepirovirsen (GSK3228836) | GSK | Closed |
| Nov 9, 2022 | Phase 3 multicenter, randomized, double blind, study to assess the efficacy and safety of treatment with bepirovirsen in hbeag negative nucleos(t)ide analogue…Bepirovirsen (GSK3228836) | GSK | Closed |
| Mar 30, 2022 | Randomised, open-label and parallel group trial to investigate the effects of oral bi 685509 alone or in combination with empagliflozin on portal hypertension…Bi 685509 / Empagliflozin | Boehringer Ingelheim (Canada) Ltd Ltee | Pending |
| Dec 21, 2020 | A phase 2b multi-centre, randomized, open-label study to assess the efficacy and safety of sequential treatment with GSK3228836 followed by pegylated…Bepirovirsen (GSK3228836)/ Peginterferon ALFA-2A | GSK | Closed |
| Jul 21, 2020 | An open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in patients with chronic hepatitis B via intrahepatic…Bepirovirsen (GSK3228836, isis 505358) | GSK | Closed |
| Jul 15, 2003 | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation | Cubist Pharmaceuticals | Designated |
| Mar 8, 1995 | Hepatitis B immune globulin intravenous (human)Prophylaxis against hepatitis B virus reinfection in liver transplant patients. | Biotest Pharmaceuticals Corporation | Designated |
| Feb 18, 2021 | Heplisav BHepatitis B surface antigen | Dynavax GmbH | EMA ↗ |
| Sep 25, 2017 | Entecavir AccordEntecavir · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 18, 2017 | Entecavir Viatris (previously Entecavir Mylan)Entecavir · generic | Viatris Limited | EMA ↗ |
| Nov 30, 2009 | ZutectraHuman hepatitis B immunoglobulin | Biotest Pharma GmbH | EMA ↗ |
| Jun 26, 2006 | BaracludeEntecavir | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Feb 2, 2005 | FendrixHepatitis B (rDNA) vaccine (adjuvanted, adsorbed) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA